Join our daily newsletter At The Bell to receive exclusive market insights
Neuren Pharma (ASX:NEU) has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome (PMS) – the first ever to be conducted.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
A rare disorder, PMS ultimately leads to developmental disabilities in children with the condition that acts on chromosomes. The condition can be inherited genetically, but it can also form sporadically on its own.
The FDA approval for Neuren’s Phase 3 trial comes on the back of a meeting it held with regulators in the U.S. establishing primary endpoints for the study.
In other words: Deciding what milestones the company would put in place to determine whether or not its drug NNZ-2591 is effective in treating PMS. (For the study to satisfy FDA’s internal scientific standards, a general methodology needs to be determined.)
That methodology is fairly stock standard: The double-blind study will give some patients NNZ-2591, while others will receive a placebo.
Caregivers and clinicians will also give feedback data with one key area of focus being communication – as in, whether or not children who take NNZ-2591 during these trials do improve their ability to follow verbal instructions and then interpret other information compared to the placebo group.
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
While the FDA needs to give another final approval before the trial kicks off around halfway through 2025, this penultimate step has made its investors happy.
And that may be a boost Neuren shareholders needed to hear – Neuren’s one-year returns are down -48% YoY.
NEU last traded at $11.03/sh.
Join the discussion: See what HotCopper users are saying about Neuren Pharma and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
